Literature DB >> 3534142

Turnover of glial filaments in mouse spinal cord.

S J DeArmond, Y L Lee, H A Kretzschmar, L F Eng.   

Abstract

Twenty-day-old mice received a single tail vein injection of [guanido-14C]arginine. The cytoskeleton was extracted from the spinal cords at varying lengths of time thereafter. Glial fibrillary acidic protein (GFAP) formed a distinct, broad band that was widely separated from other protein bands in one-dimensional polyacrylamide gels. The purity of the GFAP band was verified by Western blot analysis of one- and two-dimensional electrophoretic patterns. In addition, enzyme-linked immunosorbent assay and quantitative Western blot analysis indicated that 95% of the total spinal cord GFAP was extracted in the cytoskeletal preparation. The specific activity of GFAP was obtained by eluting the protein from the cytoskeletal GFAP band in preparative one-dimensional gels. Specific activity reached a peak 2 h after injection with [14C]arginine. Forty percent of the incorporated radioactivity was still present in cytoskeletal GFAP at 9 weeks, indicating that a significant proportion of glial filaments turns over relatively slowly in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3534142     DOI: 10.1111/j.1471-4159.1986.tb13084.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

1.  Drug screening to identify suppressors of GFAP expression.

Authors:  Woosung Cho; Michael Brenner; Noel Peters; Albee Messing
Journal:  Hum Mol Genet       Date:  2010-06-10       Impact factor: 6.150

2.  Astrocytic TGF-β signaling limits inflammation and reduces neuronal damage during central nervous system Toxoplasma infection.

Authors:  Egle Cekanaviciute; Hans K Dietrich; Robert C Axtell; Aaron M Williams; Riann Egusquiza; Karen M Wai; Anita A Koshy; Marion S Buckwalter
Journal:  J Immunol       Date:  2014-05-23       Impact factor: 5.422

3.  Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.

Authors:  Tracy L Hagemann; Berit Powers; Curt Mazur; Aneeza Kim; Steven Wheeler; Gene Hung; Eric Swayze; Albee Messing
Journal:  Ann Neurol       Date:  2018-01-14       Impact factor: 10.422

4.  Photoperiod interacts with food restriction in performance in the Barnes maze in female California mice.

Authors:  Michael Q Steinman; Katie K Crean; Brian C Trainor
Journal:  Eur J Neurosci       Date:  2010-12-31       Impact factor: 3.386

5.  Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease.

Authors:  Laura R Moody; Gregory A Barrett-Wilt; Michael R Sussman; Albee Messing
Journal:  J Biol Chem       Date:  2017-02-21       Impact factor: 5.157

6.  Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways.

Authors:  Guomei Tang; Zhenyu Yue; Zsolt Talloczy; Tracy Hagemann; Woosung Cho; Albee Messing; David L Sulzer; James E Goldman
Journal:  Hum Mol Genet       Date:  2008-02-14       Impact factor: 6.150

7.  Dual transgenic reporter mice as a tool for monitoring expression of glial fibrillary acidic protein.

Authors:  Woosung Cho; Tracy L Hagemann; Delinda A Johnson; Jeffrey A Johnson; Albee Messing
Journal:  J Neurochem       Date:  2009-05-05       Impact factor: 5.372

Review 8.  Dysfunctions of neuronal and glial intermediate filaments in disease.

Authors:  Ronald K H Liem; Albee Messing
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

9.  Profiling of dynamically changed gene expression in dorsal root ganglia post peripheral nerve injury and a critical role of injury-induced glial fibrillary acidic protein in maintenance of pain behaviors [corrected].

Authors:  Doo-Sik Kim; Katherine W Figueroa; Kang-Wu Li; Amin Boroujerdi; Tim Yolo; Z David Luo
Journal:  Pain       Date:  2009-05       Impact factor: 6.961

10.  GFAP expression as an indicator of disease severity in mouse models of Alexander disease.

Authors:  Paige L Jany; Tracy L Hagemann; Albee Messing
Journal:  ASN Neuro       Date:  2013       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.